


Patent claims

1. A compound of the formula

5



in which

10 R^1 denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, halogen, carbamoyl, cyano, hydroxyl, (C₁-C₆-alkyl)carbonyl, trifluoromethyl, trifluoromethoxy, nitro, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

15 where

R^5 and R^6 independently of one another denote for C₁-C₆-alkyl or

20 R^5 and R^6 , together with the nitrogen atom to which they are bonded, denote a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

R^2 denotes C₁-C₆-alkyl or C₃-C₄-cycloalkyl,

25 R^3 denotes methyl,

A denotes oxygen or NH,

and

5 R^4 denotes C_6-C_{10} -aryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, formyl, carboxyl, carbamoyl, cyano, hydroxyl, trifluoromethyl, trifluoromethoxy, nitro, C_1-C_6 -alkyl, C_1-C_6 -alkoxy, 1,3-dioxapropane-1,3-diyl, C_1-C_6 -alkylthio and $-NR^7R^8$,

10 in which

R^7 and R^8 independently of one another denote hydrogen, C_1-C_6 -alkyl or C_1-C_6 -alkylcarbonyl,

and their salts, solvates and/or solvates of the salts.

15

2. A compound as claimed in claim 1, where

20 R^1 denotes 5- to 10-membered heteroaryl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of oxo, C_1-C_6 -alkyl, C_1-C_6 -alkoxy and $-NR^5R^6$,

where

25 R^5 and R^6 independently of one another denote C_1-C_6 -alkyl or

R^5 and R^6 , together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C_1-C_6 -alkyl or C_1-C_6 -hydroxyalkyl,

30 R^2 denotes C_1-C_6 -alkyl,

R^3 denotes methyl,

A denotes oxygen or NH,

5 and

R^4 denotes phenyl, which can be substituted by up to 3 substituents selected independently of one another from the group consisting of halogen, C₁-C₆-alkyl and C₁-C₆-alkoxy,

10

and their salts, solvates and/or solvates of the salts.

3. A compound as claimed in claim 1 and 2, where

15

R^1 denotes thienyl, furyl, thiazolyl or pyridyl, which in each case can be substituted by up to 2 substituents selected independently of one another from the group consisting of oxo, C₁-C₆-alkyl, C₁-C₆-alkoxy and -NR⁵R⁶,

20

where

R^5 and R^6 independently of one another denote C₁-C₆-alkyl or

25

R^5 and R^6 , together with the nitrogen atom to which they are bonded, form a 5 to 8-membered heterocycle, which is optionally substituted by C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,

R^2 denotes C₁-C₆-alkyl,

30


R^3 denotes methyl,

A denotes oxygen or NH,

R⁴ denotes phenyl, which is substituted by up to 3 C₁-C₆-alkoxy radicals,

5 and their salts, solvates and/or solvates of the salts.

4. A process for the preparation of compounds as claimed in claim 1, characterized in that compounds of the general formula




10

in which

R¹, R² and R³ have the meanings indicated in claim 1,

15

are reacted with compounds of the formula



20

in which

R⁴ and A have the meanings indicated in claim 1,

to give compounds of the formula (I) and these are optionally reacted with the appropriate (i) solvents and/or (ii) bases or acids to give their solvates, salts and/or solvates of the salts.

- 5 5. A compound as claimed in one of claims 1 to 3 for the treatment and/or prophylaxis of diseases.
- 10 6. A medicament containing at least one of the compounds as claimed in one of claims 1 to 3 and at least one pharmaceutically tolerable, essentially nontoxic vehicle or excipient.
- 15 7. The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament for the treatment and/or prophylaxis of neurodegenerative disorders.
- 15 8. The use of the compounds as claimed in one of claims 1 to 3 for the production of a medicament for the treatment and/or prophylaxis of cancer, neurodegenerative disorders and psychiatric disorders.
- 20 9. The use as claimed in claim 7, where the neurodegenerative disorder is Parkinson's disease.
- 20 10. The use as claimed in claim 8, where the psychiatric disorder is schizophrenia.
- 25 11. A process for the control of cancer, neurodegenerative disorders and psychiatric disorders in a human or animal by administration of an efficacious amount of the compounds from claims 1 to 3.
- 30 12. The process as claimed in claim 11, where the neurodegenerative disorder is Parkinson's disease.

13. The process as claimed in claim 11, where the psychiatric disorder is schizophrenia.